Business Context and Reporting Period
This Form 8-K is a current report filed by AgeX Therapeutics, Inc. (not Serina Therapeutics, Inc.) on August 14, 2023. The filing serves to announce the company's financial results for the quarter and six months ended June 30, 2023. AgeX is an emerging growth company incorporated in Delaware, with its principal executive offices in Alameda, California. Its common stock trades on the NYSE American under the symbol AGE.
Key Financial Metrics
The filing text itself does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are referenced as being detailed in the press release furnished as Exhibit 99.1 to this report. Consequently, no specific financial figures can be extracted from the provided text.
Material Changes
The filing does not explicitly detail material changes versus prior periods within the body text. It directs readers to the attached press release (Exhibit 99.1) for the announcement of results for the quarter and six months ended June 30, 2023.
Guidance, Outlook, and Risks
- Forward-Looking Statements: The filing includes a standard disclaimer that statements containing words such as "may," "will," "believes," or "expects" are forward-looking and subject to risks and uncertainties.
- Risk Factors: Investors are directed to the "Risk Factors" section of AgeX's periodic reports filed with the SEC for additional factors that could cause actual results to differ materially from anticipated results.
- Update Obligation: AgeX disclaims any intent or obligation to update forward-looking statements except as required by law.
Investor Verification Checklist
- Verify the specific financial results (revenue, net loss, cash position) by reviewing Exhibit 99.1 (the press release dated August 14, 2023), as the 8-K text only references these figures.
- Confirm the company name is AgeX Therapeutics, Inc. (Ticker: AGE), noting the discrepancy in the request metadata which listed "Serina Therapeutics, Inc."
- Review the "Risk Factors" in the company's most recent 10-K or 10-Q filings to understand the specific contingencies affecting the business.
- Check the company's status as an emerging growth company and its election regarding the extended transition period for new accounting standards.